USA: FDA Publishes Draft Guidelines for the Development and Management of Medical Devices With Artificial Intelligence
In January 2025, the US Food and Drug Administration (FDA) published draft guidelines on the development and management of artificial intelligence (AI) -enabled Medical Devices, entitled: “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations”.
The long-awaited document responds to a growing demand for regulation and clarity in the area of health technology. This initiative represents an important step in defining standards of security and effectiveness for devices that integrate artificial intelligence systems, such as machine learning.
The 67-page draft proposes the adoption of a total product life cycle approach: Total Product Life Cycle (TPLC). This approach aims to ensure that devices not only meet initial requirements but remain safe and effective throughout their lifetime on the market.
The document offers detailed guidance on how manufacturers can manage AI-based devices during the development, production and post-marketing phases. In particular, the guidance suggests how to deal with changes in data systems, manage AI training and ensure transparency in automated decision-making processes. It also includes practical examples of how to properly document devices with the FDA.
Highlights
- TPLC approach: FDA recommends constant monitoring and evaluation of devices during their life cycle, considering the evolution of AI technologies and challenges in terms of emerging risks.
- Data systems and user interfaces: the draft focuses on the importance of proper data management and interactions with the end user so that devices are easy to understand.
- Proactive updates: the guidance also includes references to the Predetermined Change Control Plan (PCCP), which suggests how to plan product updates, avoiding the need for new pre-marketing requests for minor changes.
Impact on Manufacturers
This draft guidance is a valuable resource for manufacturers of AI Medical Devices, as it provides a roadmap on how to navigate FDA regulation, based on experience with already authorised devices. Moreover, the FDA points out that more than a thousand AI-based Medical Devices have already been approved, which highlights the growing importance of this type of technology in the healthcare landscape.
Manufacturers of Medical Devices using artificial intelligence systems will have to pay close attention to these new guidelines, which could determine not only compliance but also the reliability and market success of their products.
Opportunities for Public Comment
FDA has opened a public consultation window for the draft guidelines, inviting stakeholders to comment on the document until April 7, 2025, to contribute to the final definition of the guidelines.
>>> Experts from Thema and US-based Thema Corp are ready to provide regulatory support throughout the entire lifecycle of Medical Devices, including those integrating artificial intelligence systems.
01/22/2025
